Pacific Biosciences Of California (PACB) Net Margin (2010 - 2026)
Pacific Biosciences Of California's quarterly Net Margin came in at 22.26% in Q1 2026, up 112455.0% year-on-year from N/an in Q1 2025, and up 75.39% quarter-over-quarter from 90.43% in Q4 2025.
Pacific Biosciences Of California has reported Net Margin for 17 years, with the latest figure at 22.26% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 112455.0% year-over-year to 22.26%; the trailing twelve-month figure through Mar 2026 stood at 80.34% (up 35137.0% YoY), and the FY2025 full-year result was 341.47%, down 14029.0% from the prior year.
- Net Margin for Q1 2026 stood at 22.26%, up from 90.43% in the prior quarter.
- The five-year high for Net Margin was 6.04% in Q4 2024, with the low at 1146.81% in Q1 2025.
- Average Net Margin over 5 years is 230.57%, with a median of 151.94% recorded in 2024.
- Year-over-year, Net Margin plunged 94537 bps in 2025 and surged 112455 bps in 2026.
- Tracing PACB's Net Margin over 5 years: stood at 308.5% in 2022, then surged by 54 bps to 140.55% in 2023, then soared by 104 bps to 6.04% in 2024, then plunged by 1596 bps to 90.43% in 2025, then soared by 75 bps to 22.26% in 2026.
- The last three Net Margin figures came in at 22.26% (Q1 2026), 90.43% (Q4 2025), and 98.85% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 12.75% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.00% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 16.74% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 8.01% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | -22.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.26% |
| Dec 31, 2025 | -90.43% |
| Sep 30, 2025 | -98.85% |
| Jun 30, 2025 | -105.44% |
| Mar 31, 2025 | -1,146.81% |
| Dec 31, 2024 | 6.04% |
| Sep 30, 2024 | -151.94% |
| Jun 30, 2024 | -481.27% |
| Mar 31, 2024 | -201.44% |
| Dec 31, 2023 | -140.55% |
| Sep 30, 2023 | -120.07% |
| Jun 30, 2023 | -146.79% |
| Mar 31, 2023 | -226.26% |
| Dec 31, 2022 | -308.50% |
| Sep 30, 2022 | -238.22% |
| Jun 30, 2022 | -201.30% |
| Mar 31, 2022 | -245.68% |
| Dec 31, 2021 | -192.48% |
| Jun 30, 2021 | -134.47% |
| Mar 31, 2021 | -122.42% |
| Dec 31, 2020 | 276.15% |
| Sep 30, 2020 | -124.24% |
| Jun 30, 2020 | -137.75% |
| Mar 31, 2020 | -211.41% |
| Dec 31, 2019 | -66.58% |
| Sep 30, 2019 | -131.32% |
| Jun 30, 2019 | -101.64% |
| Mar 31, 2019 | -187.27% |
| Dec 31, 2018 | -160.05% |
| Sep 30, 2018 | -139.24% |
| Jun 30, 2018 | -103.55% |
| Mar 31, 2018 | -126.69% |
| Dec 31, 2017 | -84.83% |
| Sep 30, 2017 | -94.30% |
| Jun 30, 2017 | -125.61% |
| Mar 31, 2017 | -96.88% |
| Dec 31, 2016 | -72.75% |
| Sep 30, 2016 | -69.89% |
| Jun 30, 2016 | -90.93% |
| Mar 31, 2016 | -101.13% |
| Dec 31, 2015 | -5.06% |
| Sep 30, 2015 | 13.46% |
| Jun 30, 2015 | -48.41% |
| Mar 31, 2015 | -113.49% |
| Dec 31, 2014 | -110.15% |
| Sep 30, 2014 | -44.27% |
| Jun 30, 2014 | -166.33% |
| Mar 31, 2014 | -162.61% |
| Dec 31, 2013 | -193.75% |
| Sep 30, 2013 | -277.87% |
| Jun 30, 2013 | -341.77% |
| Mar 31, 2013 | -377.07% |
| Dec 31, 2012 | -370.21% |
| Sep 30, 2012 | -815.81% |
| Jun 30, 2012 | -310.30% |
| Mar 31, 2012 | -274.06% |
| Dec 31, 2011 | -68.47% |
| Sep 30, 2011 | -299.80% |
| Jun 30, 2011 | -11,803.65% |
| Mar 31, 2011 | -12,950.74% |
| Dec 31, 2010 | -13,067.50% |
| Sep 30, 2010 | -18,498.18% |
| Jun 30, 2010 | -5,194.75% |